Higher than Physician's Desk Reference (US) doses on atypical antipsychotics

Expert Opinion on Drug Safety

Volumn 4, Issue 4, 2005, Pages 653-668

  Goodnick, Paul J ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotic; Aripiprazole; Bipolar disorder; Dosing; Olanzapine; Quetiapine; Risperidone; Treatment; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DIPHENHYDRAMINE; HALOPERIDOL; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ABDOMINAL PAIN; AGITATION; AKATHISIA; AMNESIA; ANXIETY; ASTHENIA; BACKACHE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DELUSION; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG INFORMATION; DRUG LABELING; DYSPEPSIA; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HALLUCINATION; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; LETHARGY; MANIA; METABOLIC DISORDER; MUSCLE HYPOTONIA; NAUSEA; NEGATIVE SYNDROME; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSONISM; POSITIVE SYNDROME; PSYCHOSIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; RESTLESS LEGS SYNDROME; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; URINE RETENTION; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PRODUCT LABELING; PSYCHOTIC DISORDERS; REFERENCE VALUES; SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 21744447534     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.4.653     Document Type: Review

References (77)

1. Physicians Desk Reference, 58 edition. Montvale: Thomson PDR, 2004.
2. GUTIERREZ R: Safety & efficacy of once daily risperidone in treatment of schizophrenia (poster). Presented at the 6th World Congress of Biological Psychiatry, Nice, France, 22-27 June, 1997.
3. BORISON: Risperidone versus haloperidol in acute exacerbation of schizophrenia. Presented at First Investigator's meeting of risperidone, Paris, France, 3 September 2002.
4. MARDER SR, DAVIS J: The effects of risperidone on the five dimensions of schizophrenia derived from factor analysis: Combined results of the North American trials. J. Clin. Psychiatry (1997) 58:538-546.
5. PSEUKENS (on behalf of the Risperidone Study Group): Risperdal on treatment of chronic schizophrenia, a multi-national multi-centered double blind parallel group study versus haloperidol. Br. J. Psychiatry (1995) 66:712-726.
6. CSERNANSKY JG, MAHMOUD R, BRENNER R et al.: A comparison of risperidone and haloperidol for prevention of relapse in patients with schizophrenia. N. Engl. J. Med. (2002) 346:16-22.
7. HIRSCHFIELD RM: A rapid, anti-manic effect of risperidone monotherapy, a three week multi-centered double blind placebo controlled trial. Am. J. Psychiatry (2004) 161:1057-1065.
8. KHANNA S, VIETA E, LYONS B et al.: Risperidone in treatment of acute bipolar mania double blind placebo controlled study of 290 patients (poster). Presented at 16th Congress of European College of Neuropsychopharmacology (ECNP), Prague, Czech Republic, 20-24 Sepcember 1993.
9. SACHS GS, GROSSMAN F, GHAEMI N, OKAMOTO A, BOWDEN CL: Combination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and Safety. Am. J. Psychiatry (2002) 159:1146-1154.
10. YATHAM LN, GROSSMAN F, AUGUSTYNS I, VIETA E, RAVINDRAN A: Mood stabilisers plus risperidone or placebo in treatment of acute mania. Br. J. Psychiatry (2003) 182:141-147.
11. BEASLEY CM Jr, SANGER T, SATTERLEE W et al.: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (1996) 124(1-2):159-167.
12. BEASLEY CM Jr, TOLLEFSON G, TRAN P et al.: Olanzapine versus haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (1996) 14(2):111-123.
13. TOHEN M, SANGER TM, MCELROY SL et al.: Olanzapine versus placebo in the treatment of acute mania. Am. J. Psychiatry (1999) 156:702-709.
14. TOHEN M, JACOBS T, GRUNDY SL et al.: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch. Gen. Pychiatry (2000) 57:841-849.
15. TOHEN M, CHENGAPPA KN, SUPPES T et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valoproate or lithium monotherapy. Arch. Gen. Psychiatry (2002) 59:62-69.
16. Data on File, Lilly Laboratories.
17. BREIER A, MEEHAN K, BIRKETT M et al.: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry (2002) 59:441-448.
18. WRIGHT P, BIRKETT M, DAVID SR et al.: Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry (2001) 158:1149-1151.
19. MEEHAN KM, ZHANG, DAVID SR et al.: A double-blind, randomized comparison of efficacy & safety of intramuscular injection of olanzapine, lorazepam, and/or placebo in the treatment of acutely agitated patients with bipolar mania. J. Clin. Psychopharmacol. (2001) 21:389-397.
20. ARVANITIS LA, MILLER BG: Multiple fixed doses of quetiapine (SEROQUEL) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Psychiatry (1997) 42:233-246.
21. SMALL JG, HIRSCH SR, ARVANITIS LA et al.: Quetiapine in patients with schizophrenia: a high and low dose double blind comparison with placebo. Arch. Gen. Psychiatry (1997) 54(6):549-557.
22. KING DL, LINK CGG, KOWALCYK B: A comparison of bid and tid dose regimens of quetiapine (SEROQUEL) in the treatment of schizophrenia. Psychopharmacology (1998) 137(2):139-146.
23. BRECHER M: Quetiapine monotherapy for acute mania associated with bipolar disorder. Presented at the 5th International Conference on Bipolar Disorder, Pittsburgh, PA, USA, 12-14 June 2003.
24. BOWDEN CL, GRUNZE H, MULLEN J et al.: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry (2005) 66:111-121.
25. SACHS G, CHENGAPPA K, SUPPES T et al.: Quetiapine with lithium or divalproex for the treatment of mania: a randomized, double blind, placebo-controlled study Bipolar Disorders (2004) 6:213-223.
26. KECK P, BUFFENSTEIN A, FERGUSON J et al.: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (1998) 140:173-184.
27. DANIEL DG, ZIMBROFF DL, POTKIN SG et al.: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology (1999) 20:491-505.
28. Data on File, Pfizer, Inc
29. Data on File, Pfizer, Inc
30. Data on File, Pfizer, Inc.
31. KECK PE Jr, VERSIANI M, POTKIN S et al.: Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry (2003) 160:741-748.
32. SEGAL S, RIESENBERG RA, ICE K et al.: Ziprasidone in Mania: Double-blind, Placebo-controlled Trial. Program and Abstracts of the American Psychiatric Association Institute on Psychiatric Service, Boston, MA, USA, October 2003.
33. KANE JM, CARSON WH, SAHA AR et al.: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry (2002) 63:763-771.
34. POTKIN SG, SAHA AR, KUJAWA MJ et al.: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry (2003) 60:681-690.
35. Data on File, Bristol-Myers Squibb.
36. Data on File, Briscol-Myers Squibb.
37. KECK PE, MARCUS R, TOURKODIMITRIS S et al.: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry (2003) 160:1651-1658.
38. SACHS G, SANCHEZ R, MARCUS R et al.: Aripiprazole versus Placebo in acute mania [poster]. Presented at 55th Institute on Psychiatric Services Meeting, Boston, MA, USA, 29 October - 2 November, 2003.
39. CONLEY RR, TAMMINGA CA, BARTKO JJ et al.: Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry (1998) 155:914-920.
40. TOLLEFSON GD, BIRKETT MA, KIESLER GM et al.: Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry (2001) 49:52-63.
41. VOLAVKA J, CZOBOR P, SHEITMAN B et al.: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry (2002) 159:255-262.
42. CONLEY RR, KELLY DL, RICHARDSON CM et al.: High dose olanzapine versus clozapine in treatment-resistant schizophrenia: a pilot double-blind crossover study. Biol. Psychiatry (2002) 51(8 Suppl.):21.
43. DURSUN SM, GARDNER DM, BIRD DC et al.: Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study. Can. J. Psychiatry (1999) 44:701-704.
44. MARTIN J, GOMEZ JC, GARCIA-BERNARDO E et al.: Olanzapine in treatment-refractory schizophrenia: results of open-label study. J. Clin. Psychiatry (1997) 58:479-483.
45. DOSSENBACH RK, BEUZEN JN, AVNON M et al.: The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin. Ther. (2000) 22:1021-1034.
46. LINDENMAYER JP, VOLAVKA J, LIEBERMAN J et al.: Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective study. J. Clin. Psychopharmacol. (2001) 21(4):448-453.
47. LINDENMAYER JP, CZOBOR P, VOLAVKA J et al.: Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: An open-label switch study. J. Clin. Psychiatry (2002) 63:931-935.
48. KARAGIANIS JL, LEDREW KK, WALKER DJ: Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: A one-year open-label study with five year followup. Curr. Med. Res. Opin. (2003) 19(6):473-480.
49. BALDACCHINO M, STUBBS JH, NEVISON-ANDREWS D: The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital. Pharm. J. (1998) 260:207-209.
50. SHEITMAN BB, LINDGREN JC, EARLY J et al.: High dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry (1997) 154(11):1626.
51. LAUNER MA: High dose olanzapine in treatment resistant schizophrenia. Schizophr. Res. (1998) 29(1-2):149-150.
52. MOUNTJOY CQ, BALDACCHINO AM, STUBBS JH: British experience with high dose olanzapine for treatment refractory schizophrenia. Am. J. Psychiatry (1999) 156(1):158-159.
53. REICH J: Use of high dose olanzapine in refractory psychosis. Am. J. Psychiatry (1999) 156(4):661.
54. HEIMANN SW: High dose olanzapine in an adolescent. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(5):496-497.
55. ALAO AO, ARMENTA WA, YOLLES JC: High dose olanzapine in schizophrenia. Ann. Pharmacother. (1999) 33:1228.
56. FANOUS A, LINDENMAYER JP: Schizophrenia and schizoaffective disorder treated with high doses of olanzapine. J. Cin. Pychopharmacol. (1999) 19(3):275-276.
57. LERNER V: High dose olanzapine for treatment refractory schizophrenia. Clin. Neuropharmacol. (2003) 26(2):58-61.
58. DINEEN S, WITHROW K, VORONOVITCH L et al.: QTc prolongation and high dose olanzapine. Psychosomatics (2003) 44(2):174-175.
59. KOSKY N: A possible association between high normal and high dose olanzapine and prolongation of the PR interval. J. Psychopharmacol. (2002) 16(2):181-182.
60. KELLY DL, CONLEY RR, RICHARDSON CM et al.: Adverse effects and laboratory parameters of high-close olanzapine versus clozapine in treatment-resistant schizophrenia. Ann. Clin. Psychiatry (2003) 15(3-4):181-186.
61. BRONSON BD, LINDENMAYER JP: Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. J. Clin. Psychopharmacol. (2000) 20(3):382-384.
62. NELSON MW, REYNOLDS R, KELLY DL et al.: Safety and tolerability of high dose quetiapine in treatment refractory schizophrenia: preliminary results from an open label trial [poster]. Presented at the International Congress on Schizophrenia Research, Colorado Springs, CO, USA, 29 March - 2 April, 2003.
63. NAGY J: Short-term benefits of higher dose quetiapine (up to 1600 mg/day) are maintained long term. European Psychiatry (Paris) (2004) 19(Suppl. 1):178S, Abs P105.
64. PIERRE JM, WIRSHING DA, CANNELL J et al.: High dose quetiapine in treatment resistant schizophrenia. Biol. Psychiatry (2003) 53(8 Suppl. S):188S, Abstract 532.
65. BROOKS JO.: Successful outcome using quetiapine in a case of treatment-resistant schizophrenia [abstract]. Int. J. Neuropsychopharmacol. (2000) 3(Suppl. 1):S160 Abs P.01.254. Access AN59578
66. ROBERTSON JB, TREOSTI L, WALKER KD: Successful use of high dose quetiapine in a patient with a psychiatric disorder resistant to olanzapine [abscract]. Eur. Neuropsychopharmacol. (2000) 10(Suppl. 3):S319-320 Abs P.2.096. Access AN60365
67. BOBES J, GARCIA-PORTILLA MP, SAIZ PA et al.: High degree of tolerability for monotherapy with high doses of quetiapine: a case report. J. Clin. Psychiatry (2002) 63(11):1048-1049.
68. ALTAMURA C, MADARO D, SALVADORI D: Quetiapine in acute mania: a case report (with a six month followup). Int. J. Psych. Clin. Pract. (2001) 5(4):283-285.
69. SOKOLSKI KN, BROWN BJ, MELDEN M: Urinary retention following repeated high-dose quetiapine. Ann. Pharmacother. (2004) 38(5):899-900.
70. MICELI JJ, SHIOVITZ T, SWIFT RH et al.: Effects of oral ziprasidone and haloperidol on QTc at clinical and high doses (poster). Presented at the American College of Nurse Practionerss Meeting (ACNP) 14 December, 2002.
71. DEUTSCHMAN DA, DEUTSCHMAN DH.: High dose ziprasidone: effectiveness and tolerability in clinical practice (poster). Presented at the 55th Annual Meeting of the American Pychiatric Association Institute on Psychiatric Services (APA-ISP), 29 October - 2 November, Boston, MA, USA, 2003.
72. DEUTSCHMAN DA, DEUTSCHMAN DH: High dose ziprasidone: efficacy and tolerability in clinical practice (poster). Presented at the 157th Annual Meeting of the American Psychiatric Association (APA), New York, NY, USA 1-6 May, 2004
73. MICELI JJ, ANZIANO RJ, SWIFT RH et al.: IM ziprasidone and IM haloperidol have comparable effects on QTc at Cmax (poster). Presented at the 155th meeting of the American Psychiatric Association (APA), Philadelphia, PA, USA, 18-23 May, 2002.
74. BROOKS, LUCEY JV, GUNN KP et al.: Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J. Clin. Psychiatry (2000) 61:933-941.
75. Data on File, Pfizer, Inc.
76. SAHA AR, ALI M, INGENTIO GG et al.: Safety and tolerability of aripiprazole at doses higher than 30 mg (poster). Presented at the 23rd Collegicum Internationale Neuropsychopharmacoligicum Congress Meeting, Montreal, Canada, 23-27 June, 2002.
77. GUPTA S, CHOHAN M, MADHUSOODANAN S: Treatment of acute mania with aripiprazole in an older adult with noted improvement in coexisting Parkinson's disease. Prim. Care Companion J. Clin. Psychiatry (2004) 6(1):50-51.